Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress aXess graft demonstrated excellent patency
Xeltis raises €32 million to drive clinical development of world's most advanced restorative cardiovascular devices New investors DaVita Venture Group and Invest-NL join syndicate of international
Therapeutics developer Lead Pharmaceutical (Oss, Netherlands) and French medicinal chemistry and custom synthesis company Oxeltis, have been awarded an €800K ($842K) grant from EUREKA Eurostars for a three year project aimed at developing a first-in-class small molecule therapy for diffuse large B-cell lymphoma (DLBCL). Click to read more.